Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors-Reference-Cited by-同舟云学术

Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors

Published:2015-09-16 Issue:6 Volume:33 Page:1206-1216
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Faivre Sandrine J.,Olszanski Anthony J.,Weigang-Köhler Karin,Riess Hanno,Cohen Roger B.,Wang Xuejing,Myrand Scott P.,Wickremsinhe Enaksha R.,Horn Candice L.,Ouyang Haojun,Callies Sophie,Benhadji Karim A.,Raymond Eric

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-015-0286-7.pdf

Reference25 articles.

1. Gemzar Summary of Product Characteristics (SPC) http://agence-prd.ansm.sante.fr/html/par_eu/20110907_fr390_gemcitabinemylan_spc.pdf . Accessed 24 November 2014

2. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN (1991) A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491–498

3. Patel SR, Gandhi V, Jenkins J, Papadopolous N, Burgess MA, Plager C, Plunkett W, Benjamin RS (2001) Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 19:3483–3489

4. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402–3408

5. Sakamoto H, Kitano M, Suetomi Y, Takeyama Y, Ohyanagi H, Nakai T, Yasuda C, Kudo M (2006) Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trial. J Gastroenterol 41:70–76

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Novel Fluorescent Gemcitabine Prodrug That Follows a Nucleoside Transporter‐Independent Internalization and Bears Enhanced Therapeutic Efficacy With Respect to Gemcitabine;Chemistry – A European Journal;2024-08-19

2. Pharmacogenomics Testing in Phase I Oncology Clinical Trials: Constructive Criticism Is Warranted;Cancers;2022-02-23

3. The evolution of nucleosidic analogues: self-assembly of prodrugs into nanoparticles for cancer drug delivery;Nanoscale Advances;2021

4. Small Molecular Gemcitabine Prodrugs for Cancer Therapy;Current Medicinal Chemistry;2020-10-08

5. Drug repurposing of pyrimidine analogs as potent antiviral compounds against human enterovirus A71 infection with potential clinical applications;Scientific Reports;2020-05-18